VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) --  Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through AI-powered drug discovery proudly congratulates partner, Variational AI, on being honored as the 2025 Emerging Company of the Year – Biotech by Life Sciences BC. This prestigious award recognizes a British Columbia-based biotechnology company demonstrating exceptional progress and achi ...

Award Recognition underscores the importance of AI-driven drug discoveryVANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through AI-powered drug discovery proudly congratulates partner, Variational AI, on being honored as the 2025 Emerging Company of the Year – Biotech by Life Sciences BC. This prestigious award recognizes a British Columbia- ...

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape. A Transformative AI BackdropArtificial intelligenc ...

VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointment of Dr. David M. Kideckel, Ph.D., MBA, as Chief Financial Officer (CFO), subject to approval from the TSX Venture Exchange (“TSXV”). Dr. Kideckel brings nearly two decades of experience in life sciences, ...

文章核心观点 - 拉科维纳疗法公司宣布任命叶夫根尼·梅舍列科夫和大卫·基德克尔为董事会成员，迈克尔·利格特退休，此次任命体现公司加强财务、资本市场和治理基础设施的决心，助力药物开发和市场扩张里程碑 [1][6] 公司人事变动 - 公司宣布任命叶夫根尼·梅舍列科夫和大卫·基德克尔为董事会成员，需获多伦多证券交易所创业板批准，迈克尔·利格特从董事会退休，梅舍列科夫将接替利格特担任审计委员会主席 [1] 新董事介绍 - 叶夫根尼·梅舍列科夫是经验丰富的金融高管和注册专业会计师，有超20年跨公共实践、私营企业和公共市场的经验，曾担任加拿大区块链基础设施公司TAAL的首席财务官，擅长财务治理、跨境税务战略和监管合规 [2][3] - 大卫·基德克尔是基德克尔咨询集团创始人，为上市公司和私营企业提供财务和资本市场服务，也是西斯科斯联合公司合伙人，专注生命科学领域财务会计战略，有近20年行业、咨询和资本市场经验，曾在强生和亚力兄制药等公司担任高管 [4][5] 退休董事贡献 - 迈克尔·利格特在医疗保健和资本市场领域经验丰富，对公司战略方向和发展贡献显著，其领导推动了公司为癌症患者提供创新治疗的使命 [8] 公司业务介绍 - 拉科维纳疗法公司是一家生物制药研究公司，专注开发创新癌症治疗方法，基于人工智能技术，利用专有平台审查和优化候选药物，已建立独特的DNA损伤反应抑制剂管线，目标是与制药合作伙伴合作推进候选药物进入人体临床试验 [9][10]